Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine.

ABSTRACT:

Background

Protein-based vaccines for coronavirus disease 2019 (COVID-19) provide a traditional vaccine platform with long-lasting protection for non-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogens and may complement messenger RNA vaccines as a booster dose. While NVX-CoV2373 showed substantial early efficacy, the durability of protection has not been delineated.

Methods

The PREVENT-19 vaccine trial used a blinded crossover design; the original placebo arm received NVX-CoV2373 after efficacy was established. Using novel statistical methods that integrate surveillance data of circulating strains with post-crossover cases, we estimated placebo-controlled vaccine efficacy and durability of NVX-CoV2373 against both pre-Delta and Delta strains of SARS-CoV-2

SUBMITTER: Follmann D 

PROVIDER: S-EPMC11259228 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature